Ah, nope. You haven't missed anything. And, ah, yep. You're exactly correct the way you stated it.
Today was about COMFORT-II, which was es-US PIII testing of Ruxolitinib; and back in December was about COMFORT-I, which was US PIII testing of Ruxolitinib. All of that lovely testing is now SUCCESSFULLY completed and in da' bag!
Novartis does indeed own the ex-US rights to Ruxolitinib, and they may indeed have been conducting the COMFORT-II trial, but all of that is part of the agreement of the Incyte-Novartis worldwide collaboration and license agreement. And Incyte's name is still (most definitely) a part of that agreement, which makes today's news equally as relevant to INCY as to Novartis.